Automated Molecular Diagnostic System Transforms Lab Experience
Posted on 10 May 2023
Molecular diagnostics has revolutionized the treatment and management of diseases. Molecular diagnostics can detect inherited conditions, infectious diseases, and cancer, allowing medical providers to accurately diagnose conditions, discover risk factors, and guide treatment. Now, an automated molecular diagnostic system offers high sample throughput without sacrificing quality and facilitates efficient and precise testing for infectious diseases using various assays.
The BioCode MDx-3000 molecular diagnostic system from Applied BioCode, Inc. (Santa Fe Springs, CA, USA) is a user-friendly instrument based on a 96-well microplate format. It automates detection steps, PCR amplification, and hybridization and target capture. The cost-effective, high-throughput multiplex system features a simple design with a touch screen, handheld scanner, and LIS connectivity. It allows for simultaneous testing of up to three different panels in a single run and minimizes the risk of contamination.
The BioCode MDx-3000 system supports efficient and accurate testing for infectious diseases by utilizing BioCode assays, such as the Gastrointestinal Pathogen Panel, Respiratory Pathogen Panel, CoV-2 Flu Plus Assay, and SARS-CoV-2 Assay. The BioCode Gastrointestinal Pathogen Panel employs reliable Barcoded Magnetic Beads technology to detect specific gastrointestinal microbial nucleic acid from individuals exhibiting infection signs and symptoms. The flexible, cost-effective, comprehensive molecular test identifies the 17 most common causative pathogens in raw stool specimens or stool in Cary-Blair medium from symptomatic patients.
The BioCode Respiratory Pathogen Panel is a qualitative multiplexed nucleic acid-based in vitro diagnostic test that can simultaneously detect and identify nucleic acids from multiple viruses and bacteria extracted from nasopharyngeal swab (NPS) samples obtained from individuals with signs and/or symptoms of respiratory tract infection. The BioCode CoV-2 Flu Plus Assay is a multiplexed nucleic acid test designed for the qualitative detection and differentiation of RNA from SARS-CoV-2, Influenza A, Influenza B, and/or Respiratory Syncytial Virus (RSV) in nasopharyngeal swabs. It can be run as an independent assay or concurrently with the FDA-cleared BioCode Respiratory Pathogen Panel to provide a more comprehensive respiratory infection profile for patients. The BioCode SARS-CoV-2 Assay is designed to detect two different conserved regions of the SARS-CoV-2 N gene.
Related Links:
Applied BioCode, Inc.
